Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Atnahs Pharma UK Limited, Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR, United Kingdom
Inderal 10 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Pink, round, biconvex, intagliated with “10” on one face and bisected on the reverse face. Diameter of each film-coated tablet is approximately 6.5 mm. The score line is not intended for breaking the tablet. |
ach tablet contains 10 mg propranolol hydrochloride.
Excipient(s) with known effect: Lactose – 79 mg of lactose per tablet.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Propranolol |
Propranolol is a competitive antagonist at both beta, and beta2-adrenoceptor, but has membrane stabilising activity at concentrations exceeding 1-3mg/litre, though such concentrations are rarely achieved during oral therapy. Competitive beta-blockade has been demonstrated in man by a parallel shift to the right in the dose-heart rate response curve to beta-agonists such as isoprenaline. |
| List of Excipients |
|---|
|
Core: Lactose Coating: Carmine (E120) |
PVC-PVDC/Al blisters available in pack size of 50 tablets (5 × 10 tablets).
Atnahs Pharma UK Limited, Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR, United Kingdom
PL 43252/0036
Date of first authorisation: 27th May 1975
Date of latest renewal: 4th June 2003
| Drug | Countries | |
|---|---|---|
| INDERAL | Austria, Australia, Canada, Germany, Japan, Malta, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
